INTRODUCTION AND OBJECTIVES:
We conducted a retrospective study to examine whether a history of non-muscle invasive bladder cancer (NMIBC) plays a prognostic role in radical cystectomy (RC)-treated patients with cT2-T4a muscle invasive bladder cancer (MIBC) without lymph node involvement. We also evaluated whether neoadjuvant chemotherapy may be equally effective in initially diagnosed MIBC patients without a history of NMIBC (i.e. primary MIBC) and those that progressed from NMIBC (i.e. progressive MIBC).
METHODS: We identified a total of 282 patients who were diagnosed as cT2-T4aN0M0 bladder cancers, treated with open RC and were having no lymph node involvement at our institutions between 2004 and 2015. We compared the clinic-pathological characteristics and clinical outcome according to the type of MIBC (primary MIBC, N[231 vs progressive MIBC, N[51) .
RESULTS: The primary MIBC group had 48.1% of patients in cT2, 40.7% in cT3, and 11.3% in cT4, while the progressive MIBC group had 72.5% in cT2, 17.6% in cT3, and 9.8% in cT4 (p[0.004). In overall, the 5-year cancer-specific survival (CSS) rate in progressive MIBC group was 61.6%, which was significantly lower than that in primary MIBC group (76.1%, p[0.005, figure below). Progressive MIBC (Hazard Ratio; HR of 2.170, p[0.008) was independently associated with cancer death. In primary MIBC group, the 5-year CSS rate in patients treated with neoadjuvant chemotherapy was 85.4%, which was significantly higher than those without (71.5%, p[0.023) and multivariate Cox's regression analysis revealed that pathological T3 or more, LN dissected of 8, and LVI positivity were independently associated with cancer death. In progressive MIBC group, no significantly difference on CSS was observed between patients treated with and without neoadjuvant chemotherapy and pathological T3 or more and a positive surgical margin were independently associated with cancer death.
CONCLUSIONS: MIBC progressed from NMIBC had significantly worse clinical outcome as compared to MIBC without a history of NMIBC and might have less efficacy for neoadjuvant chemotherapy. These results would be informative even for NMIBC patients treated with conservative intravesical therapy. 
Radical cystectomy is the standard surgical therapy for muscle-invasive bladder cancer. The RAZOR trial, which compared robot-assisted cystectomy to open found no difference in two-year progression-free survival. However, little is known about the cost differences between these two techniques. We sought to evaluate differences in costs between the approaches.
METHODS: The Healthcare Cost and Utilization Project State Inpatient Databases for FL, MD, NY, and WA from 2012-2014 was queried. Patients with a diagnosis of bladder cancer (ICD-9 188x, 233.7) who had undergone radical cystectomy (ICD-9 57.71) were identified. Surgical approach was categorized as open or robot-assisted (ICD-9 17.4x). Costs were estimated from reported charges using hospital-specific cost to charge ratios. Rates of complications, LOS, and costs of care include all readmissions for 90 days following surgery. Univariate analysis was performed using Student's t-test, Pearson chi-square test, and Wilcoxon rank-sum test. A multivariable linear regression model was used to determine predictors of overall cost. RESULTS: 4,250 patients who underwent radical cystectomy for bladder cancer were identified. Of these, 23% were performed with robot assistance. The robotic approach was associated with lower rates of sepsis (7.15% vs. 10.36%, p[0.003), wound complications (6.13% vs 9.66%, p[0.001), pneumonia (3.17% vs 5.20%, p[0.019) , and an improved overall LOS (9 vs 10 days, p<0.005). There was no difference in 90 day readmission rate (38.95% vs 38.71%, p[0.496) 
